Treatment for Congenital Cytomegalovirus Infection: who, for how long, with what Drug Regimen?

Bernhard Resch*

Department of Paediatrics, Medical University of Graz, Austria

Congenital cytomegalovirus (CMV) infection is the most frequently identified viral cause of mental retardation and is the leading non-genetic cause of neurosensory hearing loss in developed countries, and is the most common congenital infection in human beings, with approximately 1% of all infants born alive in the United States being infected with CMV [1-3]. Infants with symptomatic CMV infection with observations at birth including petechiae, hepatosplenomegaly, microcephaly, thrombocytopenia, or jaundice with conjugated hyperbilirubinemia showed in 70% of cases normal computed tomographic (CT) scans with intracerebral calcification being the most frequent finding, and again 90% of the children with an abnormal newborn CT scan developed at least one sequelae [4]. In addition, almost half of the children with CT abnormalities had an IQ <50 compared with none of those with a normal CT. Of infected fetuses, approximately 10% are symptomatic at birth, and 90% of symptomatic survivors have significant neurologic sequelae, including hearing deficits in 30% to 65% [5,6].

CMV load in cord vein blood was found to be significantly lower than that in urine, thus, the CMV load in urine seems to reflect organ involvement and effect of therapy best. Nevertheless, determination of CMV DNA in cord vein blood is the most rapid diagnostic test for congenital CMV infection [7].

There are currently four antiviral drugs licensed for the treatment of CMV infections: ganciclovir (GCV), valganciclovir (VGCV), foscarnet (FOS), and cidofovir (CDV) [8,9]. These drugs have provided major advances in CMV disease management, although they are limited by intolerable toxicities, oral bioavailability and efficacy, and risk of drug resistance with extended use.

Searching for evidence based or scientific guidelines for selection of newborns with congenital CMV infection that might benefit from treatment with ganciclovir Smets et al. [10] identified 13 case reports (16 patients in all), three descriptive uncontrolled studies (20 patients in all), two randomized dose-comparative studies (54 patients in all) and one randomized controlled study (42 patients) with all patients presenting with central nervous system (CNS) manifestation of CMV infection. Kimberlin and co-workers [11] published the only prospective randomized controlled study by enrolment of 100 infants from 18 US centres between 1991 and 1999. Infants ≤1 month of age, ≥32 weeks’ gestation, and weighing ≥1200 g at birth having evidence of CNS disease, such as (1) microcephaly; (2) intracranial calcifications; (3) abnormal cerebrospinal fluid for age; (4) chorioteratitis; and/or (5) hearing deficits were eligible for study participation. Patients were randomly assigned to receive ganciclovir treatment (6 mg/kg per dose administered intravenously every 12 hours for 6 weeks) or no treatment. Of these, 42 patients had both a baseline and 6-month follow-up audiometric examination and thus were evaluable for the primary end point (improved brainstem-evoked response, BERAs). Twenty-one (84%) of 25 ganciclovir recipients had improved hearing or maintained normal hearing between baseline and 6 months versus 10 (59%) of 17 control patients (p=0.06). None (0%) of 25 ganciclovir recipients had worsening in hearing between baseline and 6 months versus 7 (41%) of 17 control patients (p<0.01). The authors concluded that ganciclovir therapy having begun in the neonatal period in symptomatically infected infants with CMV infection involving the CNS prevents hearing deterioration at 6 months and may prevent hearing deterioration at ≥1 year. The most common side effect of ganciclovir therapy was significant neutropenia in almost two thirds of treated infants during therapy. Six years following the publication of this trial the group published the impact of ganciclovir therapy on neurodevelopmental outcomes (Olivier 2009) and found fewer developmental delays at 6 and 12 months (p=.02 and .007, respectively). The authors claimed that data cannot be extrapolated to neonates with other manifestations of CMV disease including asymptomatic babies and symptomatic babies who do not have CNS involvement.

On the basis of the above mentioned study a target AUC12 (area under the concentration–time curve over a 12-h period) of 27 mg X h/L was defined in a prospective pharmacokinetic and pharmacodynamic study of the use of valganciclovir in symptomatic CMV disease [12]. The median dose of oral valganciclovir administered was 16 mg/kg, which produced a geometric mean AUC12 of 27.4 mg X h/L with a bioavailability of 41.1%. Interestingly, infants who started the study with higher viral burden experienced greater decreases in viral load but did not clear virus during the 42-day course of therapy. Neutropenia developed in 38% of subjects; that was markedly lower compared to ganciclovir with 64%.

Uncontrolled case series advocate a more prolonged course of therapy for optimal outcome, partially with oral valganciclovir and apparently without higher risk of side effects [13-16]. Divergent regimens of oral valganciclovir therapies in symptomatic [17-25] and even asymptomatic [26,27] cases of congenital CMV infection were reported more recently. A multi-centre, prospective, international, phase III, randomized and blinded investigation of six weeks versus six months of oral valganciclovir therapy in babies with symptomatic congenital CMV disease is currently underway [28]. At this time, however, by lack of controlled trials, there is no real evidence for longer treatment.

The major benefit from ganciclovir or valganciclovir treatment in infants with congenital CMV might be a preservation of hearing, at least in the intermediate term. Smets and the working goup members [10] felt that newborns with severe hearing loss who repeatedly reach thresholds of ≥100 dB at BERA audiometry should not be treated
with ganciclovir. They argue that even with some improvement in hearing abilities, these infants are very likely to need cochlear implants anyway. Smets et al. would recommend inclusion of babies with CNS manifestations of CMV infection (excluding isolated striatal vasculopathy and isolated single periventricular pseudocyst) and newborns with growth retardation and/or petechiae for ganciclovir therapy. The authors although advocated that there is no literature data on treatment of asymptomatic children; this should only be done within the setting of a clinical trial, and such trials should preferably include asymptomatic babies with high viral load, as they are at higher risk of hearing loss.

More recent evidence based management guidelines for the treatment of congenital CMV infection are based on the decision whether the baby is asymptomatic or symptomatic, and the latter is defined as CNS symptomatic disease (as described above) and severe focal organ disease including severe hepatitis, severe bone marrow suppression (all three cell lines), colitis or pneumonitis [29]. In their management algorithm for the treatment of congenital CMV the authors recommend a six weeks course of either intravenous ganciclovir or oral valganciclovir with dosage regimens as described above. All asymptomatic or mild to moderate symptomatic infants with congenital CMV infection should not receive treatment. A close follow-up of all infants whether treated or not is mandatory.

In conclusion there is still lack of evidence on successful antiviral treatment of symptomatic congenital CMV infection especially regarding long-term positive effects on either hearing or neurodevelopmental impairment beyond the first year of age. Oral valganciclovir therapy seems to be as effective as intravenous ganciclovir during a six weeks course of treatment. The effects of longer courses of oral valganciclovir treatment have still to be evaluated and results of the CASG trial have to be awaited until further recommendations can be given.

References